Join Growin Stock Community!

Fibrobiologics, inc. common stockFBLG.US Overview

US StockHealthcare
(No presentation for FBLG)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

FBLG AI Insights

FBLG Overall Performance

FBLG AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

FBLG Recent Performance

11.56%

Fibrobiologics, inc. common stock

0.05%

Avg of Sector

-0.31%

S&P500

FBLG PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

FBLG Key Information

FBLG Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

FBLG Profile

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Price of FBLG

FBLG FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

FBLG Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.44
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
150.55
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.44
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
150.55
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%

  • When is FBLG's latest earnings report released?

    The most recent financial report for Fibrobiologics, inc. common stock (FBLG) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating FBLG's short-term business performance and financial health. For the latest updates on FBLG's earnings releases, visit this page regularly.

  • How much debt does FBLG have?

    As of the end of the reporting period, Fibrobiologics, inc. common stock (FBLG) had total debt of 2.41M, with a debt ratio of 0.25. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does FBLG have?

    At the end of the period, Fibrobiologics, inc. common stock (FBLG) held Total Cash and Cash Equivalents of 4.89M, accounting for 0.51 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is FBLG's EPS continuing to grow?

    According to the past four quarterly reports, Fibrobiologics, inc. common stock (FBLG)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.03. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of FBLG?

    Fibrobiologics, inc. common stock (FBLG)'s Free Cash Flow (FCF) for the period is -3.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 0.28% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of FBLG?

    The latest valuation data shows Fibrobiologics, inc. common stock (FBLG) has a Price-To-Earnings (PE) ratio of -0.97 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.